- Home
- CCIA vs XOMAP Comparison
CCIA vs XOMAP Comparison
Compare CCIA & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- XOMAP
- Stock Information
- Founded
- CCIA N/A
- XOMAP N/A
- Country
- CCIA
- XOMAP United States
- Employees
- CCIA N/A
- XOMAP 13
- Industry
- CCIA
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- XOMAP Health Care
- Exchange
- CCIA Nasdaq
- XOMAP Nasdaq
- Market Cap
- CCIA N/A
- XOMAP N/A
- IPO Year
- CCIA 2023
- XOMAP N/A
- Fundamental
- Price
- CCIA $25.75
- XOMAP $25.75
- Analyst Decision
- CCIA
- XOMAP
- Analyst Count
- CCIA 0
- XOMAP 0
- Target Price
- CCIA N/A
- XOMAP N/A
- AVG Volume (30 Days)
- CCIA N/A
- XOMAP N/A
- Earning Date
- CCIA N/A
- XOMAP N/A
- Dividend Yield
- CCIA N/A
- XOMAP N/A
- EPS Growth
- CCIA N/A
- XOMAP N/A
- EPS
- CCIA N/A
- XOMAP N/A
- Revenue
- CCIA N/A
- XOMAP N/A
- Revenue This Year
- CCIA N/A
- XOMAP N/A
- Revenue Next Year
- CCIA N/A
- XOMAP N/A
- P/E Ratio
- CCIA N/A
- XOMAP N/A
- Revenue Growth
- CCIA N/A
- XOMAP N/A
- 52 Week Low
- CCIA N/A
- XOMAP N/A
- 52 Week High
- CCIA N/A
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- CCIA 55.35
- XOMAP 50.70
- Support Level
- CCIA $25.53
- XOMAP $25.58
- Resistance Level
- CCIA $25.81
- XOMAP $25.87
- Average True Range (ATR)
- CCIA 0.10
- XOMAP 0.11
- MACD
- CCIA -0.00
- XOMAP -0.00
- Stochastic Oscillator
- CCIA 78.57
- XOMAP 47.83
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.